Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?

Jurriën M. Ten Berg; Vera H. Deneer

doi:10.1038/nrcardio.2012.29

Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?

Jurriën M. Ten Berg
, Vera H. Deneer

St. Antonius Ziekenhuis

Research output: Contribution to journal › Review article › peer-review

Abstract

Commenting on the results of their meta-analysis, Holmes et al. suggest that CYP2C19 genotype does not affect clinical outcome in patients receiving clopidogrel therapy. However, we do not believe that the data support this conclusion; an association between genotype and outcome remains plausible and could be considered when choosing treatment.

Original language	English
Pages (from-to)	192-194
Number of pages	3
Journal	Nature Reviews Cardiology
Volume	9
Issue number	4
DOIs	https://doi.org/10.1038/nrcardio.2012.29
Publication status	Published - 1 Apr 2012

Access to Document

10.1038/nrcardio.2012.29

Cite this

@article{4f9ffe933c0f4402bcb885d5090e668b,

title = "Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?",

abstract = "Commenting on the results of their meta-analysis, Holmes et al. suggest that CYP2C19 genotype does not affect clinical outcome in patients receiving clopidogrel therapy. However, we do not believe that the data support this conclusion; an association between genotype and outcome remains plausible and could be considered when choosing treatment.",

author = "\{Ten Berg\}, \{Jurri{\"e}n M.\} and Deneer, \{Vera H.\}",

year = "2012",

month = apr,

day = "1",

doi = "10.1038/nrcardio.2012.29",

language = "English",

volume = "9",

pages = "192--194",

journal = "Nature Reviews Cardiology",

issn = "1759-5002",

publisher = "Nature Research",

number = "4",

}

TY - JOUR

T1 - Antiplatelet therapy

T2 - Does CYP2C19 genotype affect clinical outcome?

AU - Ten Berg, Jurriën M.

AU - Deneer, Vera H.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Commenting on the results of their meta-analysis, Holmes et al. suggest that CYP2C19 genotype does not affect clinical outcome in patients receiving clopidogrel therapy. However, we do not believe that the data support this conclusion; an association between genotype and outcome remains plausible and could be considered when choosing treatment.

AB - Commenting on the results of their meta-analysis, Holmes et al. suggest that CYP2C19 genotype does not affect clinical outcome in patients receiving clopidogrel therapy. However, we do not believe that the data support this conclusion; an association between genotype and outcome remains plausible and could be considered when choosing treatment.

UR - https://www.scopus.com/pages/publications/84859100321

U2 - 10.1038/nrcardio.2012.29

DO - 10.1038/nrcardio.2012.29

M3 - Review article

C2 - 22411289

AN - SCOPUS:84859100321

SN - 1759-5002

VL - 9

SP - 192

EP - 194

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

IS - 4

ER -

Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?

Abstract

Access to Document

Other files and links

Fingerprint

Cite this